Literature DB >> 8608984

Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children.

G Vassal1, M J Terrier-Lacombe, A Lellouch-Tubiana, C A Valery, C Sainte-Rose, J Morizet, P Ardouin, G Riou, C Kalifa, A Gouyette.   

Abstract

The histogenesis of medulloblastoma, also described as a cerebellar primitive neuro-ectodermal tumor (PNET), remains controversial and unresolved. In addition, genetic markers which characterize cerebellar PNETs with poor prognosis in children have not been identified. Since xenografts can be valuable tools for better understanding the genetic events involved in cerebellar PNETs, small fragments of tumor samples from 17 children with newly diagnosed cerebellar PNETs were transplanted s.c. into female athymic Swiss mice. Eleven were non-metastatic and 6 were metastatic PNETs. Eight tumors (47%) were tumorigenic. Histological analysis showed 6 typical medulloblastomas, 1 PNET with melanin pigment and 1 PNET with a rhabdoid phenotype. Wide heterogeneity was observed in tumor growth, with a doubling time ranging from 8 to 81 days after the first passage. Tumorigenicity was correlated with the metastatic phenotype of the tumor (p < 0.001). All the patients but one with a tumorigenic tumor relapsed and died. The survival of patients with a non-tumorigenic PNET (67%) was significantly higher than that of patients with a tumorigenic PNET (13%) (p < 0.02). None of the xenografts or tumors from patients exhibited N-myc-gene alteration. Only one xenograft showed c-myc amplification, with an abnormal 15-kilobase fragment. None of the 17 tumors from patients showed amplification or c-myc-gene rearrangement. In conclusion, tumorigenicity of cerebellar PNETs strongly correlates both with the metastatic phenotype of the tumors and with the disease-free survival of the patients. In addition, genetic events other than c-myc-gene amplification might be involved in cerebellar PNETs with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608984     DOI: 10.1002/(SICI)1097-0215(19960422)69:2<146::AID-IJC14>3.0.CO;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

2.  Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Authors:  Estelle Daudigeos-Dubus; Ludivine Le Dret; Claudia Lanvers-Kaminsky; Olivia Bawa; Paule Opolon; Albane Vievard; Irène Villa; Mélanie Pagès; Jacques Bosq; Gilles Vassal; Dieter Zopf; Birgit Geoerger
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

3.  New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis.

Authors:  Alexandre Plessier; Ludivine Le Dret; Pascale Varlet; Kévin Beccaria; Joëlle Lacombe; Sébastien Mériaux; Françoise Geffroy; Laurence Fiette; Patricia Flamant; Fabrice Chrétien; Thomas Blauwblomme; Stéphanie Puget; Jacques Grill; Marie-Anne Debily; David Castel
Journal:  Oncotarget       Date:  2017-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.